DBV Technologies | DBVT - Interest Expense On Debt

Stock Price
22.39
Daily Change
0.80 3.71%
Monthly
31.78%
Yearly
394.26%
Q1 Forecast
21.05

DBV Technologies reported $461K in Interest Expense on Debt for its fiscal quarter ending in March of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amarin USD 3K 5K Dec/2024
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
DBV Technologies USD 461K 323.71K Mar/2025
Halozyme Therapeutics USD 4.3M 98K Sep/2025
Incyte USD 592K 2K Sep/2025
Insmed USD 20.38M 863K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
United Therapeutics USD 3M 4.3M Sep/2025